Why IMNN matters now
Imunon, Inc. (IMNN) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.59 with -3.05% on the session and $6.7M in market capitalization; recent performance reads 1-month -18.39% and YTD -52.23%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.2M, and EPS of $-0.84. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -328.1%.
The latest indexable market news headline is "Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Lindborg Stacy filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.72
P/S
0.00
EV/EBITDA
-0.05
DCF Value
$3.07
FCF Yield
-328.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-341.2%
ROA
-182.6%
ROIC
-346.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.2M | $-0.84 |
| Q4 2025 | $0.00 | $-4.2M | $-1.99 |
| FY 2025 | $0.00 | $-14.5M | $-6.83 |
| Q3 2025 | $0.00 | $-3.4M | $-1.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.93
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.